JAMP Pharma Group launches PrPexegra® (pegfilgrastim) and PrFilra® (filgrastim), two new biosimilar therapeutic options in oncology

• JAMP Pharma Group launches ^PrPexegra®, a biosimilar alternative to the reference product ^PrNeulasta® (commercialized in Canada by Amgen Canada Inc.).
• JAMP Pharma Group also launches ^PrFilra®, a biosimilar alternative to the reference product ^PrNeupogen® (commercialized in Canada by Amgen Canada Inc.).
• JAMP Pharma Group, through its BioJAMP® division, is strengthening its portfolio of biosimilar products. Two new products, ^PrPexegra® and ^PrFilra®, are being added to the existing biologic portfolio ^PrSimlandi® and ^PrJamteki®, marking the company's entry into the field of oncology.
• With its growing oncology portfolio, which includes biosimilars and specialty care molecules, JAMP Pharma Group reaffirms its commitment to improving access to treatment for patients and supporting healthcare professionals in Canada.
• As a Canadian-based and owned organization, the JAMP Pharma Group is proud to contribute to the health and well-being of Canadians while supporting the local economy.

BOUCHERVILLE, QC, Sept. 24, 2025 /CNW/ - JAMP Pharma Group, a leading Canadian pharmaceutical organization, is proud to announce today the launch of two biosimilar products in oncology, ^PrPexegra® and ^PrFilra®.

^PrPexegra® is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-neoplastic drugs¹.

^PrFilra® is indicated for reducing the frequency of infections manifested by febrile neutropenia in patients with non-myeloid malignancies receiving myelosuppressive antineoplastic agents, and in patients with severe congenital, idiopathic, or cyclic neutropenia².

These two launches will expand the range of treatment options for patients. ^PrPexegra® and ^PrFilra® are among the biosimilars of pegfilgrastim and filgrastim, respectively, that are currently authorized for sale in Canada by a Canadian-owned company. As a result, JAMP Pharma Group is committed to improving access to affordable care for Canadian patients.

"We are extremely proud to add ^PrPexegra® and ^PrFilra® to our growing biosimilars portfolio. This marks the first oncology biosimilar products for our BioJAMP® division", said Louis Pilon, President and CEO of the JAMP Pharma Group. "These launches align with our mission to provide diverse therapeutic solutions to Canadian patients and are a testament to our expertise in biosimilars."

^PrPexegra® is currently authorized for sale by Health Canada as a preservative-free solution (0.6 mL) containing 6 mg of pegfilgrastim (10 mg/mL) in a single-dose prefilled syringe with a 27 gauge, ½ inch needle with an UltraSafe Plus™ Passive Needle Guard, to reduce the risk of accidental needle sticks for users¹.

^PrFilra® is currently authorized for sale by Health Canada in the form of 0.5 mL single-use pre-filled syringe, without preservatives and also equipped with an UltraSafe Plus™ passive needle protection device, containing 300 mcg of filgrastim (600 mcg/mL). The 0.8 mL single-use pre-filled syringe, without preservatives and equipped with an UltraSafe Plus™ passive needle protection device, contain 480 mcg of filgrastim (600 mcg/mL). ^PrFilra® is distributed in boxes of 1 and in boxes of 10 syringes².

A robust pipeline to meet the needs of Canadians

The JAMP Pharma Group, through its BioJAMP® division, has a robust pipeline of projects aimed at expanding its biosimilars offering, both in oncology and other therapeutic areas. Its existing portfolio includes products in immunology, such as ^PrSimlandi® and ^PrJamteki®. Through strategic partnerships, the company is committed to providing Canadian patients with ongoing access to advanced and cost-effective treatments.

About the JAMP Pharma Group

The JAMP Pharma Group is a Canadian organization headquartered in Boucherville, in the Greater Montreal area. Having experienced exceptional growth over the past ten years, the JAMP Pharma Group is present in all segments of the pharmaceutical market, with a portfolio of more than 380 molecules and is one of the industry leaders in annual prescription volume³. With over 130 new products authorized for sale by Health Canada in the last three years, the JAMP Pharma Group is the Canadian leader in product launches⁴, enhancing the new treatment options available in Canada, including many specialty drugs. The addition of a new local manufacturing site supports the JAMP Pharma Group's vision of becoming the largest Canadian-owned pharmaceutical company.

In addition to its generic division, the JAMP Pharma Group has several divisions, such as Orimed, BioJAMP®, Wampole, Laboratoire Suisse and Cosmetic Import and Acute Care & Injectables, offering prescription and branded products, biosimilars, 180 over-the-counter products and a wide range of vitamins, supplements and natural health products. The JAMP Care^TM patient support program is designed to help patients and healthcare professionals using specialty drugs and biosimilars offered by the JAMP Pharma Group.

The inclusion of Amgen Canada Inc is solely to indicate product availability through their distribution network. The use of Amgen Canada Inc's trademark does not imply any endorsement, sponsorship or affiliation. All trademarks remain the property of their respective owners.

Sources:

¹Product Monograph, ^PrPexegra®. Available on Health Canada's website:
https://pdf.hres.ca/dpd_pm/00078045.PDF

²Product Monograph, ^PrFilra®. Available on Health Canada's website:
https://pdf.hres.ca/dpd_pm/00080022.PDF

³Source: Based on market data from an independent source.

⁴Source: Based on market data from an independent source.

SOURCE Corporation JAMP Pharma

For further information, please contact: [email protected]